Structure via PubChem · Public domain (PubChem)
netarsudil
Sign in to saveAlso known as (4-((1S)-1-(Aminomethyl)-2-(isoquinolin-6-ylamino)-2-oxoethyl)phenyl)methyl 2,4- dimethylbenzoate
Netarsudil, sold among others under the brand name Rhopressa, is a medication for the treatment of glaucoma. In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa.
In the Vinony graph
Vinony's link graph records 60 inbound references to netarsudil, and connects out to biological half-life, brinzolamide and digital object identifier.
It sits within the topics Benzoate esters, Chemicals using indexlabels and Drug has EMA link.
Vinony links it to 9 Wikipedia language editions.
Chemical data
- Formula
- C28H27N3O3
- Molecular weight
- 453.5 g/mol
- IUPAC name
- [4-[(2S)-3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl]phenyl]methyl 2,4-dimethylbenzoate
- SMILES
- CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
- InChIKey
- OURRXQUGYQRVML-AREMUKBSSA-N
- XLogP
- 4.6
- Polar surface area
- 94.3 Ų
- H-bond donors
- 2
- H-bond acceptors
- 5
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 453.205
- Has use
- medication
Show 4 more facts
- canonical SMILES
- CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)C(CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
- chemical formula
- C₂₈H₂₇N₃O₃
- isomeric SMILES
- CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)[C@@H](CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
- subject has role
- protein kinase inhibitors
Sources (2)
via Wikidata · CC0
~2 min read
Encyclopedic overview
11 sectionsContents
- Contraindications
- Adverse effects
- Overdose
- Interactions
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Chemistry
- See also
- References
- External links
Netarsudil, sold among others under the brand name Rhopressa, is a medication for the treatment of glaucoma. In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa.
The FDA considers it to be a first-in-class medication.
Excerpted from Wikipedia’s “netarsudil” article, available under the CC BY-SA 4.0 licence.